[Cocarnit in complex therapy of diabetic peripheral polyneuropathy]

Area of Science:

• Neurology
• Pharmacology
• Diabetology

Context:

• Diabetic peripheral polyneuropathy (DPPN) significantly impacts patient quality of life.
• Current treatments often involve gabapentin, which can have dose-limiting side effects.

Purpose:

• To evaluate the efficacy of Cocarnit as a combination therapy for DPPN.
• To assess the impact of Cocarnit on pain, neuropathy symptoms, nerve conduction, and quality of life in DPPN patients.

Summary:

• A study involving 40 DPPN patients demonstrated that Cocarnit, when combined with gabapentin, led to significant pain reduction.
• Patients showed improved neuropathy symptom scores (DN4, NSS, MNSI) and enhanced quality of life.
• Nerve conduction studies indicated positive trends, particularly in peroneal nerve function.
• The combination therapy allowed for lower gabapentin doses, reducing potential side effects.

Impact:

• Cocarnit is a valuable therapeutic option for managing DPPN.
• This combination therapy offers a strategy to improve patient outcomes while mitigating gabapentin-related adverse events.
• The findings support Cocarnit's role in peripheral nerve restoration in diabetic patients.